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Abstract
While Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is
disrupting lives across the globe for everyone, it has a more devastating impact on the health of older adults, especially
that of older men. This pandemic has highlighted the crucial importance of considering an individual’s age and
biological sex in the clinic in addition to other confounding diseases (Kuchel, G.A, J Am Geriatr Soc, 67, 203, 2019,
Tannenbaum, C., Nature, 575 451-458, 2009) As an interdisciplinary team of scientists in immunology, hematology,
genomics, bioinformatics, and geriatrics, we have been studying how age and sex shape the human immune system.
Herein we reflect on how our recent findings on the alterations of the immune system in aging might contribute to
our current understanding of COVID-19 infection rate and disease risk.
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Immune system aging and COVID-19
Many parameters likely contribute to the etiology of the
COVID-19 disease. The number of viral particles (i.e., viral
load) and the mode of infection might explain why health
care workers are at a higher risk; differences in the genome of the virus strains or the genome of the host (i.e.,
genetic makeup of the patients) might account for some
of the variation observed across countries and populations. At the individual level, in addition to the aforementioned factors, a person’s immune system status is also an
important predictor of the disease outcome, which can be
shaped by the individual’s age, sex, as well as the existence
of co-morbidities.
COVID-19 shows differences in terms of which populations are vulnerable when compared to previous pandemics.
Pregnant women were at increased risk during the H1N1
pandemic in 2009 [1], whereas the H1N1 pandemic of 1918
(known as Spanish flu) particularly affected younger individuals: 15- to 34-year-olds [2]. While COVID-19 appears to
have a milder effect on these populations so far [3], increasing age of an individual clearly stands out as an important
predictor of vulnerability for COVID-19. According to data
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from China, the COVID-19 death rate is 3.6% for individuals
in their 60s, 8% for those in their 70s, 15% for individuals
older than 80, yet ~ 0.5% for individuals in their 40s (https://
www.worldometers.info/coronavirus/coronavirus-age-sexdemographics/). Such an age discrepancy is also found in
other countries. Most notably in Italy, case fatality rate for individuals in their 70s and 80s was reported as 25% and 31%
respectively (https://www.epicentro.iss.it/coronavirus/) and
the average age of patients dying from COVID-19 was 79
(based on 19,996 deaths on April 16th). Many factors can
accelerate an individual’s biological age, including
diet, exercise, lifestyle choices (smoking) and comorbidities (diabetes, obesity) [4]. Therefore, increasing age (biological and chronological) likely predispose individuals to severe COVID-19 outcomes.
Our immune system is composed of two distinct arms
with different functions: adaptive and innate immunity. Our
team [5] and other investigators [6–13] have documented
that, with aging, both arms of our immune systems go
through changes in cellular composition and in function. Innate immunity is the first line of defense against dangerous
invaders such as SARS-CoV-2, the virus that causes COVID19. The innate immune system acts through its ability to
capture and inactivate pathogens and to launch inflammation. Typically, inflammatory responses are acute; they last
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for a short time and lead to a rapid accumulation of immune
cells and proteins at the site of injury to remove the invader
and start the healing process. When acute responses are insufficient, inflammatory responses can prolong thereby affecting numerous cellular components. Aging has been
linked with such chronic activation of innate immunity, associated with low-grade and systemic (body-wide) increases in
inflammation (coined “inflamm-aging”) that can be detrimental for the body [8, 14, 15] and also conserved across tissues and organisms [16]. In other words, a biological
response that is beneficial in a healthy immune system in
youth can become a potential liability in older age [17].
Adaptive immune cells are mobilized when the innate
immune system is insufficient to defeat a threat.
Whereas innate immunity acts quickly to recognize microbes by their general features, adaptive immune cells,
B and T cells, can eliminate a threat with precision by
specifically recognizing foreign substances associated
with a certain threat (for example, a short protein fragment - an antigen - unique to SARS-CoV-2). After successfully clearing a threat/infection, the body maintains
a reserve of “memory cells” which remember how to
recognize the threat and clear it quickly in case of future
invasions. The delicate co-operation and balance between innate and adaptive immune cells are critical to
orchestrate an effective immune response at any age.
With increasing age, this balance is disrupted. In
addition to chronic activation of innate immunity, adaptive immune functions decline with age [8, 18, 19].
These declines affect the adaptive immune system’s ability i) to recognize novel threats due to a loss in the number of cells that can be educated to recognize novel
threats (i.e. naïve cells), and ii) to mount strong responses due to the accumulation of over-stimulated and
dysfunctional, “exhausted” immune cells. Recent data
suggest that with aging, some adaptive cells also change
their functionality and gain innate-like functions [20].
Preliminary data from COVID-19 patients in Wuhan
suggest that disease severity was associated with reduced
numbers of T cells (naïve and memory helper T cells,
regulatory T cells) in the blood (n = 44; 27 severe, 17
non-severe) [21]. In alignment with the global patterns,
severe cases were older than non-severe cases (median
age 61 versus 53) and included more men than women
(54% men) (n = 452; 286 severe, 166 non-severe) [21].
Older age has been associated to increased risk for developing acute respiratory distress syndrome (ARDS) [22]
(n = 201; 84 with ARDS) in COVID-19 patients, which are
the most severe cases that require ICU admission and oxygen therapy [23] (n = 41; 13 requiring ICU). Severe cases
have also been associated with increased levels of blood
pro-inflammatory cytokines [21–24]. Two of the proinflammatory proteins that were elevated in the blood of severe cases [21] have been associated with low physical
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performance among older adults: IL-6, C-reactive protein
(CRP) [15] and are considered as biomarkers of inflammaging. Serum concentrations of these molecules have also
been linked to obesity and visceral adiposity [25, 26]. Furthermore, systemic inflammation has been proposed as a
risk factor for multiple diseases [14]. Further research is
needed to establish whether the baseline levels of these proteins in the blood can predict disease severity for COVID19. Clinical trials are ongoing to assess the efficacy of reducing systemic inflammation using anti-inflammatory drugs
for severe COVID-19 patients, including humanized monoclonal antibodies that bind and block the interleukin-6 receptor (IL-6R): Tocilizumab and Sarilumab (Fig. 1).
Data from a small cohort suggest that, in severe cases,
pro-inflammatory innate immune cells expand in the lung
(n = 6 patients, 3 of which severe; n = 8 healthy controls),
whereas T cells expand in milder cases [27]. As expected,
patients with severe disease were older than those with
milder disease (median age 63 versus 36). This stark difference in the mechanisms of response to the virus between older and young patients is consistent with agerelated changes in the immune system: chronic activation
of innate immunity and functional declines in adaptive
immunity. Together these age-related changes in the immune system deteriorate an individual’s health and might
impair responses to SARS-CoV-2 in older adults.

Sex differences in infectious diseases and COVID19
In addition to an individual’s age, biological sex is an important determinant of COVID-19 disease severity. In China,
across all age groups, the death rate among confirmed cases
is 2.8% for women and 4.7% for men (https://www.worldometers.info/coronavirus/coronavirus-age-sex-demographics/). In Italy, although half of confirmed cases are men, men
account for 65% of all deaths (as of April 16th) (https://www.
epicentro.iss.it/coronavirus/). Even in countries that reported
fewer infected men than infected women, such as Spain
(49%) and Switzerland (47%), men account for 63 and 62%
of deaths, respectively based on mid-April data statistics (http://globalhealth5050.org/covid19/). This pattern is
generally consistent around the world, including in the USA
(https://www.nytimes.com/2020/04/07/health/coronavirusnew-york-men.html): on average, for each woman killed by
COVID-19, 1.5 to 2 men succumb to the virus.
It has long been known that men and women differ in
terms of risk and severity for diseases involving the immune
system [28]. Women are disproportionately affected by autoimmune disorders, whereas men are more susceptible to infectious diseases, [29], both in terms of their intensity (the severity of the disease in an individual) and prevalence (the
number of infected people in a population) [30]. Although
epidemiological data for COVID-19 cases are still missing for
many countries, among the countries that have a high
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Fig. 1 Summary of age- and sex-related changes in the immune system in relation to COVID-19. Inflammation increases with age in both sexes
with age, albeit at higher rates in men. Severe COVID-19 cases have been associated with increased inflammation markers in blood and lung. The
efficacy of anti-inflammatory drugs are in trials for COVID-19 patients. B cell numbers decline with age specifically in men. Severe cases of COVID19 have been associated with reduced B cell numbers. Convalescent plasma transfer is being investigated as a potential therapy for COVID-19
patients. T cell functions decline with age, including declining naïve T cell numbers as well as reduced ability to mount strong responses to
immune threats. Declines in T cell numbers have been observed in severe COVID-19 patients. Anti-viral drugs can be useful to boost immune cell
responses. These observations might also be useful in assessing disease risk in healthy individuals by studying their immune status. For example,
individuals who have less B/T cells, more inflammation or more monoclonal hematopoiesis, might be more prone to devastating health
consequences of COVID-19

number of infections and have reported such information,
the sex differences are striking (http://globalhealth5050.org/
covid19/), in worst cases, the difference is two-fold between
men and women in terms of death rate. Why is COVID-19
more dangerous for men, especially for older men?
The reasons for sex differences in COVID-19 are likely
multifactorial and include genetics, lifestyle differences,
co-morbidities, and hormones [28, 29]. For example, in
China, men smoke at much higher rates than women.
Smoking rates have been associated with increased activity
of ACE2 [31] - the receptor protein that is expressed on
the surface of human cells and is used as a “door” by the
SARS-CoV-2 virus. Interestingly, this gene is located on
the X chromosome. However it is unclear whether the
sex- and age-related changes in ACE2 activity is biological
[32] or is attributable to confounding factors (e.g.,
cigarette smoking [31]). Furthermore, although it has been
speculated that sex differences in China might stem from
differences in cigarette smoking rates between men and
women, data on this are inconclusive thus far [33]. Men
also have a greater incidence of chronic illnesses such as
ischemic heart disease that can impact one’s ability to fight
and survive the COVID-19 infection.

The role of genetics in sex differences
X chromosome contains the largest number of immunerelated genes in the whole genome [34], including genes

that are involved in innate (e.g., pattern recognition receptors TLR7 and TLR8 that are highly expressed on
monocytes) and adaptive immune responses (e.g., chemokine receptor CXCR3 that is highly expressed on effector T cells). It is suggested that X chromosome is
partially responsible for the hyper-responsiveness of the
female immune system – hence the increased incidences
of auto-immune diseases in women – by contributing to
the breakdown of self tolerance (i.e., immune system tolerating cells/molecules from self) [35]. Women (XX
genotype) carry twice as many X-linked genes (> 1000
genes) compared to men (XY genotype). Expression
levels of X-linked genes are balanced between sexes via a
process called X chromosome inactivation (XCI), which
transcriptionally inactivates one copy of the X chromosome. XCI is established during embryonic development
and mostly maintained throughout lifespan [36]. Although XCI is generally uniform across tissues, a recent
study conducted from 449 individuals in 29 tissues
showed that there are tissue- and individual-specific heterogeneity in XCI patterns [32]. The role of this heterogeneity in human health particularly in COVID-19 is not
known yet. Furthermore, some genes – particularly the
ones that have Y chromosome homologues – can escape
XCI, known as escapees. Hence, these genes can be
expressed from two copies: maternal and paternal. Escapee genes might also be contributing to diseases. For

Márquez et al. Immunity & Ageing

(2020) 17:13

example, single-cell analyses of women blood-derived
immune cells uncovered that the TLR7 gene is expressed
from both maternal and paternal copies in primary B
cells, monocytes, and plasmacytoid dendritic cells [37].
Furthermore, this bi-allelic expression correlated with
the increased gene and protein expression of this molecule in women, which can even be detected from peripheral blood mononuclear cells (PBMCs). TLR dosage
is considered as a key pathogenic factor in systemic
lupus erythematosus (SLE) [38]. Therefore, the increased
expression of TLR7 due to XCI escaping might contribute to higher incidences of SLE (90% of SLE patients are
women) in women as well as similar skews observed in
other auto-immune diseases. Although reports in this
area are limited, aging might also affect the XCI patterns
and contribute to age-related increases in certain gene
expression programs and susceptibility to certain diseases
in older women [39]. A future research challenge is to
dissect the role of X-linked genes in COVID-19 infections and to understand whether their role is affected
with age or with the presence of confounding diseases
and conditions (e.g., obesity).

Sex dimorphism in immune system aging in
relation to COVID-19
In addition to aforementioned lifestyle, co-morbidity,
and genetic differences, the immune systems of men and
women exhibit striking differences especially as individuals age, which might also contribute to the sex dimorphism in COVID-19 cases. Our recent work
uncovered how aging affects women’s and men’s immune systems differently [40], in terms of both the extent and the timing of age-related changes. We studied
blood-derived immune cells from 172 healthy men and
women with ages ranging from 22 to 93, who were carefully screened to exclude confounding diseases, medications, and frailty. Using genomic and functional assays,
we uncovered aging-related changes in the number of
immune cells, as well as functional differences of these
cells by analyzing their transcriptome and epigenome
maps. Among aging-related changes shared between
sexes, we observed a decline in adaptive immunity (particularly T cells), as well as an activation of innate immunity. Although both men and women exhibited these
changes, they were significantly greater in magnitude in
men, especially in terms of the activation of innate immunity and inflammation even when the subjects were
otherwise healthy and clinically comparable in terms of
age, BMI, and ethnicity [40]. In alignment with these genomic findings, serum protein level data from a separate
study showed that levels of pro-inflammatory IL6 and
IL1RA were higher in older men (65+) compared to older
women (n = 267 used for re-analyses, 500FG project) [41].
Furthermore, serum levels of these two proteins increased
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with age more significantly in men compared to women
[40]. These data suggest men experience a stronger
‘inflamm-aging’ syndrome than women. Further studies
are needed to understand whether increased systemic inflammation in older men could be the foundation of the
pro-inflammatory “cytokine storms” that characterize severe overreactions to SARS-CoV-2 virus, a phenomenon
more frequently observed in men than women [21]. Based
on a recent report from Wuhan China, pregnant women
infected with COVID-19 were mostly asymptomatic (92%,
109 out of 118) [3]. Interestingly, the majority of the severe cases among pregnant women (6 out of 9) developed
after the delivery, possibly due to the tolerance/anti-inflammatory mechanism pregnant women develop to tolerate the baby during pregnancy [42]. Together these
observations suggest that the systemic inflammation levels
can be predictive of COVID-19 disease severity. Antiinflammatory drug treatments (such as anti-IL-6 monoclonal antibodies) are already in clinical trials [24], which
might benefit individuals with high levels of systemic inflammation, including older adults – especially older men
– and obese individuals (Fig. 1). Efficacy of other antiinflammatory treatments, particularly the ones that are developed to protect older adults (geroprotective) [43] might
be considered in the future for protecting individuals
against severe COVID-19 infections.
We also uncovered striking sex differences in how the B
cell compartment age [40]. B cells are adaptive immune
cells which, upon activation, differentiate into plasma cells
and produce antibodies. These antibodies are found in the
bloodstream and at the surface of mucosae where they act
as an early barrier against infectious agents. Blood B cells
(numbers and percentages) were lower in older men (65+)
both in our cohort recruited in Connecticut (cell percentages, n = 130) and separate cohorts from France (cell percentages and numbers, n = 892) [44] and from Japan
(cell numbers, n = 356) [45], suggesting that some of these
sex-differences are conserved across populations. Reduced
B cell numbers in older men might result in reduced antibody production that might impair an individual’s ability
to fight viruses and other pathogens. In alignment with
this, COVID-19 patients with severe symptoms had three
times fewer B cells in their blood than asymptomatic patients
(109 vs. 373 cells per microliter of blood) [46], similar declining trends were observed in a smaller cohort, albeit not
reaching to statistical significance levels (n = 44) [21]. In a
pilot study of 5 critically ill COVID-19 patients, the administration of plasma from recovered patients that contains
antibodies were able to neutralize SARS-CoV-2 virus significantly and improved the patients’ clinical status [47].
Larger antibody-based treatment studies are currently ongoing (Fig. 1). Antibody based treatment strategies may
compensate for the B cell deficit of older men. However, a
safety concern is a phenomenon called antibody-
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dependent enhancement, when non-neutralizing antiviral
antibodies facilitate entry into host cells thereby increasing
the viral infectivity. This phenomenon is observed in vitro
and has been found to occur in humans infected with dengue virus or vaccinated with an early Respiratory Syncytial
Virus (RSV) vaccine [48]. This has also been observed
with anti-spike antibodies causing acute lung injury during
acute SARS-CoV infection [49].
We also observed accelerated age-related T cell function
declines in men compared to women [40], which was also
reported in the Japanese cohort (n = 356) [45]. For example,
naïve T cell frequencies decreased with age, particularly in
CD8+ T cells in both sexes, however, women had more
naïve T cells compared to men in both young and older
subjects, which was also observed in other studies [50].
Women have been shown to have elevated thymic function
compared to men at all ages [51], which might potentially
explain sex-differences in naïve T cells. Lymphopenia (having reduced numbers of lymphocytes in the blood) has been
reported in severe cases of COVID-19 in multiple studies
[21, 23, 52, 53], including drastic declines in CD4+ and
CD8+ T cells as well as NK and B cells. Together, these data
suggest that SARS-CoV-2 might impair antiviral immunity
significantly and this impairment might have more severe
consequences for older adults. Several anti-viral drugs are in
clinical trials for COVID-19, including Remdesivir that was
originally developed for Ebola patients; the US Food and
Drug Administration (FDA) recently issued an emergency
use authorization of Remdesivir for severe COVID-19 cases.

Timing of age-related changes in the immune
system
Finally, by employing statistical algorithms to model temporal trends in genomics data generated from blood samples, we showed that the timing of age-related changes in
the immune system differ between men and women. Although we noted a gradual decline in the immune system
in both men and women accruing for most of their adult
life, these changes accelerated drastically at two time points
in life. The first acceleration point occurs in both sexes at
around 40 years of age. In the context of COVID-19, this is
the age when a doubling in the death rate was reported
from 0.2 to 0.4% in China (https://www.worldometers.info/
coronavirus/coronavirus-age-sex-demographics/). Our previous work has discovered that this “middle-aged” decline
in the immune system occurs in mice also, including a drop
in production of adaptive immune cells and bias in
hematopoietic stem cell (HSC) differentiation toward overproduction of innate immune cells [54], supporting that research using model organisms can help us to understand
causative mechanisms for such genomic changes. A second
and more dramatic acceleration occurs later in life and exhibits a marked sex difference, being more pronounced and
occurring approximately 5 years earlier in men compared

Page 5 of 8

to women (early/mid-60s in men versus late-60s in
women). Interestingly, this difference between men and
women parallels the 5-year gap between sexes in terms of
the expected lifespan in the US. The period of accelerated
immune changes in the 60s roughly coincides with the uptick in the lethality of COVID-19 reported in China and
Italy. These temporal changes reflect declines in adaptive
immunity and increases in innate immunity for both sexes.
However the magnitude of changes were stronger in men,
a finding in alignment with the sex bias in cytokine storms
and the mortality of COVID-19 cases. Data from Italy –
one of the few countries that report detailed information
on sex – also support a gap between sexes in terms of experiencing the lethal effects of COVID-19 infections, where
the median age of women who have died from COVID-19
is 82 versus 78 for men (https://www.epicentro.iss.it/coronavirus/). Data and analyses on the timing of immune system changes with age might inform us on when to start
interventions and treatments for older adults. Little is currently known as to whether HSC lineage bias diverges between sexes as they age. Understanding the mechanisms by
which, and extent to which, HSC lineage bias may be distinct between men and women with aging, and determining
if this is a root cause of immune changes between men and
women, will be an important area of investigation.
Sex hormones, e.g., testosterone and oestrogen, play
diverse roles in immune responses [55], some of which
are due to the direct interactions between sex hormones
and immune cells. Immune cells can express receptors
for sex hormones suggesting that these cells can directly
respond to changing hormone levels in our body. For example, estrogen receptors (ERα and ERβ) are expressed
in a diverse array of immune cells (T, B, natural killer
cells, macrophages, DCs, neutrophils). Furthermore, the
effect of sex hormones on immune cell functions are
proposed to be dose-dependent [55]. Hence, age or
menstrual-cycle dependent changes in the sex hormone
levels might affect the interaction between sex hormones
and immune cells. Surprisingly, our comparisons of men
and women PBMCs at different ages [40] showed that
immune profiles between sexes diverge as age increases,
even though the hormone levels decrease with age.
These findings suggest that sex hormones might play
roles in balancing immune responses in men and women
and compensate for other inherent differences due to
genetics. It is also worth noting that the effect of sex
hormones is not independent of the sex chromosomes.
For example, the androgen receptor (AR), that is activated by the binding of androgenic hormones (e.g., testosterone) is coded on the X chromosome. Future
studies are needed to explore to what extent sex hormones –or lack thereof – contribute to disease severity
in COVID-19 or other relevant pathologic conditions
(e.g., systemic inflammation).
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Age-related clonal hematopoiesis and COVID-19
co-morbidities
With aging, changes in our hematopoietic (blood) stem cell
pool, which can be thought of as the “root” of the immune
system, contribute to the functional decline in both our innate and adaptive immune systems. Hematopoietic stem
cells (HSCs) accumulate somatic mutations with aging, increasing the chance that one or more HSCs in the pool will
accrue a mutation that confers a competitive fitness advantage over other HSCs. This is frequently observed in older individuals, where outgrowth of a mutated HSC and its
immune cell progeny is termed ‘clonal hematopoiesis’. In initial reports using exome sequencing to detect clonal
hematopoiesis, this condition was detectable in < 1% of individuals under age 40, increasing in frequency in each decade
of life up to an incidence of 10–20% of individuals in their
70s or older [56–58]. In addition to the increased prevalence
in aging, there are other similarities between populations susceptible to clonal hematopoiesis and COVID-19 morbidity.
Clonal hematopoiesis is more commonly observed in older
men [57]. Increasing evidence suggests that cardiovascular
comorbidities are common in patients with COVID-19, and
such patients are at higher risk of morbidity and mortality
[59]. The risk of cardiovascular disease more than doubles in
individuals with clonal hematopoiesis [57, 60], which is as
great or greater than well-described risk factors such lowdensity lipoprotein (LDL) cholesterol level and blood pressure. Mouse models of common clonal hematopoiesis mutations have established that this link is causative, causing
increased size of atherosclerotic lesions and leading to worsening heart function [60–63]. Although large, populationlevel epidemiological studies directly linking clonal
hematopoiesis to COVID-19 outcomes are currently lacking,
our understanding of immune system changes caused by
clonal hematopoiesis mutations may help to inform the design of studies to determine causality. How might clonal
hematopoiesis in aged populations increase their risk of
death from COVID-19 infection?
Our work [64] and that from other investigators [64–
69] have shown that the most common mutations found
in clonal hematopoiesis not only result in a competitive
fitness advantage in HSCs but also result in biased differentiation toward innate immune cells at the expense
of adaptive immune cells, and propensity for transformation to blood cancers within the innate immune system.
Clonal hematopoiesis mutations can increase levels of
pro-inflammatory cytokines, including IL-6, IL-1β and
IL-8, and inflammatory responses in macrophages and
mast cells [60–62, 70, 71]. Elevated levels of proinflammatory cytokines, sustained over-production of innate immune cells and reduced production of adaptive
immune cells, as a consequence of clonal hematopoiesis,
might be contributing to poor COVID-19 outcomes in
older adults.
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Systems and predictive immunology to study
COVID-19
Systems immunology is an inter-disciplinary field that generates and integrates diverse genomics and phenotypic data
to drive a systems-level understanding of immune functions
and immune disorders [72]. Recent advances in single cell
technologies provide opportunities to study gene and protein expression as well as epigenetic patterns at single cell
resolution [73, 74, 80]. Systems-level studies some of which
by taking advantage of these single cell technologies have
already been impactful in diverse immune-related conditions including but not limited to age-related decline in immune functions [5, 14, 40, 75] and vaccine responsiveness
[76], auto-immune diseases, [77, 78], and cancer [79, 80].
Generation of such datasets from human immune cells [81]
in the context of COVID-19 and proper integration of these
data using advanced computational techniques [73] will be
instrumental in answering some of the open questions related to the current health crisis. Particularly, systems-level
approaches can be effective in i) assessing risk at the individual level and dissecting how different factors contribute
to this risk (age, sex, BMI); and ii) understanding genomic
or cellular predictors of responsiveness to potential therapies. Furthermore, integrating these single cell genomic technologies with genotypes of individuals can bring further
resolution related to the role genetics play in disease risk
and in selecting appropriate therapies tailored for individual
patients [82, 83].
Conclusions
Emerging data collected from COVID-19 patients together with our findings from healthy donors drive
home a critical point: an improved understanding of
sex-specific and age-dependent immune characteristics
will lead to more informed and ultimately more effective clinical decisions. Profiling an individual’s
blood-derived immune cells is easily accessible and a
relatively cheap way to assess health and disease risk
at the individual level. Recent advances in genomics
have led to powerful tools to study the human immune system down to the single cell level resolution.
What we can learn from a small amount of blood
sample when combined with these technologies is unprecedented in detail. Furthermore, advances in computing methods (e.g., deep learning algorithms),
provide us with a unique opportunity to analyze and
interpret these data to assess health and disease risk
in an increasingly personalized and precise manner.
While we currently find ourselves in a moment of
uncertainty and desperation, we rest certain that the
future of medicine is bright given these technological
advances that can be harnessed to better understand
and cure diseases, including COVID-19 that set a
new research agenda for many scientists [84].
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